| Dr Pantelhs Pete Varlas, MD | |
|
3909 Orange Pl Ste 2100, Beachwood, OH 44122-8400 | |
| (216) 383-0100 | |
| (216) 383-6481 |
| Full Name | Dr Pantelhs Pete Varlas |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 23 Years |
| Location | 3909 Orange Pl Ste 2100, Beachwood, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134156250 | NPI | - | NPPES |
| 2461358 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 35082721 (Ohio) | Secondary |
| 207P00000X | Emergency Medicine | 35082721V (Ohio) | Primary |
| 207P00000X | Emergency Medicine | 01079908A (Indiana) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mary Rutan Hospital | Bellefontaine, OH | Hospital |
| Mercy Hospital - Aurora | Aurora, MO | Hospital |
| Wilson Memorial Hospital | Sidney, OH | Hospital |
| Perry County Memorial Hospital | Tell city, IN | Hospital |
| Van Wert County Hospital | Van wert, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ohiohealth Corporation | 6305758426 | 1900 |
News Archive
Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (sBLA) providing regular approval for Soliris® (eculizumab) for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).
The U.S. Food and Drug Administration today announced a public-private partnership to help identify counterfeit or substandard anti-malarial medicines, including falsified products, with the deployment of the FDA-developed Counterfeit Detection Device, called CD-3.
Brief pulses of ultrasound delivered to nerves near the kidney produced a clinically meaningful drop in blood pressure in people whose hypertension did not respond to a triple cocktail of medications, reports a new study led by researchers at Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian.
For those still confused about the various health reform bills - six in ten are confused, and half say they don't know enough to form an opinion, the New York Times reports - news organizations offer a series of primers on key bills and provisions today.
› Verified 4 days ago
| Entity Name | Ohiohealth Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578545273 PECOS PAC ID: 6305758426 Enrollment ID: O20031105000532 |
News Archive
Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (sBLA) providing regular approval for Soliris® (eculizumab) for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).
The U.S. Food and Drug Administration today announced a public-private partnership to help identify counterfeit or substandard anti-malarial medicines, including falsified products, with the deployment of the FDA-developed Counterfeit Detection Device, called CD-3.
Brief pulses of ultrasound delivered to nerves near the kidney produced a clinically meaningful drop in blood pressure in people whose hypertension did not respond to a triple cocktail of medications, reports a new study led by researchers at Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian.
For those still confused about the various health reform bills - six in ten are confused, and half say they don't know enough to form an opinion, the New York Times reports - news organizations offer a series of primers on key bills and provisions today.
› Verified 4 days ago
| Entity Name | Community Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730145392 PECOS PAC ID: 0547258907 Enrollment ID: O20040504000912 |
News Archive
Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (sBLA) providing regular approval for Soliris® (eculizumab) for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).
The U.S. Food and Drug Administration today announced a public-private partnership to help identify counterfeit or substandard anti-malarial medicines, including falsified products, with the deployment of the FDA-developed Counterfeit Detection Device, called CD-3.
Brief pulses of ultrasound delivered to nerves near the kidney produced a clinically meaningful drop in blood pressure in people whose hypertension did not respond to a triple cocktail of medications, reports a new study led by researchers at Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian.
For those still confused about the various health reform bills - six in ten are confused, and half say they don't know enough to form an opinion, the New York Times reports - news organizations offer a series of primers on key bills and provisions today.
› Verified 4 days ago
| Entity Name | Emergency Professional Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093762353 PECOS PAC ID: 7214832435 Enrollment ID: O20040511000864 |
News Archive
Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (sBLA) providing regular approval for Soliris® (eculizumab) for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).
The U.S. Food and Drug Administration today announced a public-private partnership to help identify counterfeit or substandard anti-malarial medicines, including falsified products, with the deployment of the FDA-developed Counterfeit Detection Device, called CD-3.
Brief pulses of ultrasound delivered to nerves near the kidney produced a clinically meaningful drop in blood pressure in people whose hypertension did not respond to a triple cocktail of medications, reports a new study led by researchers at Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian.
For those still confused about the various health reform bills - six in ten are confused, and half say they don't know enough to form an opinion, the New York Times reports - news organizations offer a series of primers on key bills and provisions today.
› Verified 4 days ago
| Entity Name | Ohio Valley Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962433177 PECOS PAC ID: 8729032966 Enrollment ID: O20050422000921 |
News Archive
Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (sBLA) providing regular approval for Soliris® (eculizumab) for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).
The U.S. Food and Drug Administration today announced a public-private partnership to help identify counterfeit or substandard anti-malarial medicines, including falsified products, with the deployment of the FDA-developed Counterfeit Detection Device, called CD-3.
Brief pulses of ultrasound delivered to nerves near the kidney produced a clinically meaningful drop in blood pressure in people whose hypertension did not respond to a triple cocktail of medications, reports a new study led by researchers at Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian.
For those still confused about the various health reform bills - six in ten are confused, and half say they don't know enough to form an opinion, the New York Times reports - news organizations offer a series of primers on key bills and provisions today.
› Verified 4 days ago
| Entity Name | Hles Of Ohio, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679806301 PECOS PAC ID: 2961549209 Enrollment ID: O20091020000137 |
News Archive
Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (sBLA) providing regular approval for Soliris® (eculizumab) for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).
The U.S. Food and Drug Administration today announced a public-private partnership to help identify counterfeit or substandard anti-malarial medicines, including falsified products, with the deployment of the FDA-developed Counterfeit Detection Device, called CD-3.
Brief pulses of ultrasound delivered to nerves near the kidney produced a clinically meaningful drop in blood pressure in people whose hypertension did not respond to a triple cocktail of medications, reports a new study led by researchers at Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian.
For those still confused about the various health reform bills - six in ten are confused, and half say they don't know enough to form an opinion, the New York Times reports - news organizations offer a series of primers on key bills and provisions today.
› Verified 4 days ago
| Entity Name | Fep Of Ohio |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134718448 PECOS PAC ID: 2062827355 Enrollment ID: O20210218002451 |
News Archive
Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (sBLA) providing regular approval for Soliris® (eculizumab) for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).
The U.S. Food and Drug Administration today announced a public-private partnership to help identify counterfeit or substandard anti-malarial medicines, including falsified products, with the deployment of the FDA-developed Counterfeit Detection Device, called CD-3.
Brief pulses of ultrasound delivered to nerves near the kidney produced a clinically meaningful drop in blood pressure in people whose hypertension did not respond to a triple cocktail of medications, reports a new study led by researchers at Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian.
For those still confused about the various health reform bills - six in ten are confused, and half say they don't know enough to form an opinion, the New York Times reports - news organizations offer a series of primers on key bills and provisions today.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Pantelhs Pete Varlas, MD Po Box 74224, Cleveland, OH 44194-0002 Ph: (216) 383-6480 | Dr Pantelhs Pete Varlas, MD 3909 Orange Pl Ste 2100, Beachwood, OH 44122-8400 Ph: (216) 383-0100 |
News Archive
Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (sBLA) providing regular approval for Soliris® (eculizumab) for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).
The U.S. Food and Drug Administration today announced a public-private partnership to help identify counterfeit or substandard anti-malarial medicines, including falsified products, with the deployment of the FDA-developed Counterfeit Detection Device, called CD-3.
Brief pulses of ultrasound delivered to nerves near the kidney produced a clinically meaningful drop in blood pressure in people whose hypertension did not respond to a triple cocktail of medications, reports a new study led by researchers at Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian.
For those still confused about the various health reform bills - six in ten are confused, and half say they don't know enough to form an opinion, the New York Times reports - news organizations offer a series of primers on key bills and provisions today.
› Verified 4 days ago
Rykiel Haley Levine, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3999 Richmond Rd, Beachwood, OH 44122 Phone: 240-686-2300 | |
Mr. Mark H Gersten, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3909 Orange Pl, Ste 2100, Beachwood, OH 44122 Phone: 216-896-1800 Fax: 216-896-1801 | |
Jason Earl Ashbaugh, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4110 Warrensville Center Rd, Beachwood, OH 44122 Phone: 216-491-6000 | |
Dr. Jordan Mcquilkin, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3999 Richmond Rd, Beachwood, OH 44122 Phone: 240-686-2300 | |
Jeremy Robert Edmiston, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4110 Warrensville Center Rd, Beachwood, OH 44122 Phone: 216-491-6000 | |
Louis Albert Horwitz, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3909 Orange Pl, Beachwood, OH 44122 Phone: 216-896-1806 | |
Dr. Aaron Daniel Lareau, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3999 Richmond Rd, Beachwood, OH 44122 Phone: 216-593-5500 Fax: 216-201-5310 |